Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT
Annalisa Paviglianiti,
Erick Xavier,
Annalisa Ruggeri,
Patrice Ceballos,
Eric Deconinck,
Jan J. Cornelissen,
Stephanie Nguyen-Quoc,
Natacha Maillard,
Guillermo Sanz,
Pierre-Simon Rohrlich,
Laurent Garderet,
Fernanda Volt,
Vanderson Rocha,
Nicolaus Kroeger,
Eliane Gluckman,
Nathalie Fegueux,
Mohamad Mohty
Affiliations
Annalisa Paviglianiti
Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France;Monacord, Centre Scientifique de Monaco, France
Erick Xavier
Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France;Monacord, Centre Scientifique de Monaco, France
Annalisa Ruggeri
Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France;Monacord, Centre Scientifique de Monaco, France;Service d’Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France
Patrice Ceballos
Département d’Hématologie Clinique, CHU Lapeyronie, Montpellier, France
Eric Deconinck
Department Hematology, CHU Besancon, France
Jan J. Cornelissen
Department of Hematology, Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, the Netherlands
Stephanie Nguyen-Quoc
Department Hematology, University Paris IV, Hôpital la Pitié-Salpêtrière, Paris, France
Natacha Maillard
Bone Marrow Transplant Unit Clinical Hematology, Hôpital La Miletrie, Poitiers, France
Guillermo Sanz
Servicio de Hematologia, Hospital Universitario y Politecnico La Fe, Valencia, Spain
Pierre-Simon Rohrlich
Hematologie Clinique, CHU - Hôpital de l’ARCHET I, Nice, France
Laurent Garderet
Service d’Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France
Fernanda Volt
Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France;Monacord, Centre Scientifique de Monaco, France
Vanderson Rocha
Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France;Monacord, Centre Scientifique de Monaco, France;Department Hematology, Churchill Hospital, Oxford, UK
Nicolaus Kroeger
Dept. Stem Cell Transplantation, University Hospital of Hamburg, Germany
Eliane Gluckman
Eurocord, APHP, University Paris Diderot, Hôpital Saint Louis, Paris, France;Monacord, Centre Scientifique de Monaco, France
Nathalie Fegueux
Département d’Hématologie Clinique, CHU Lapeyronie, Montpellier, France
Mohamad Mohty
Service d’Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France;INSERM, UMRs 938, Paris, France
Although allogeneic stem cell transplantation is not a standard therapy for multiple myeloma, some patients can benefit from this intense therapy. There are few reports on outcomes after umbilical cord blood transplantation in multiple myeloma, and investigation of this procedure is warranted. We retrospectively analyzed 95 patients, 85 with multiple myeloma and 10 with plasma cell leukemia, receiving single or double umbilical cord blood transplantation from 2001 to 2013. Median follow up was 41 months. The majority of patients received a reduced intensity conditioning. The cumulative incidence of neutrophil engraftment was 97%±3% at 60 days, and that of 100-day acute graft-versus-host disease grade II-IV was 41%±5%. Chronic graft-versus-host disease at two years was 22%±4%. Relapse and non-relapse mortality was 47%±5% and 29%±5% at three years, respectively. Three-year progression-free survival and overall survival were 24%±5% and 40%±5%, respectively. Anti-thymocyte globulin was associated with decreased incidence of acute graft-versus-host disease, higher non-relapse mortality, decreased overall and progression-free survival. Patients with high cytogenetic risk had higher relapse, and worse overall and progression-free survival. In conclusion, umbilical cord blood transplantation is feasible for multiple myeloma patients.
